318 related articles for article (PubMed ID: 28886127)
1. Genome-wide miRNA response to anacardic acid in breast cancer cells.
Schultz DJ; Muluhngwi P; Alizadeh-Rad N; Green MA; Rouchka EC; Waigel SJ; Klinge CM
PLoS One; 2017; 12(9):e0184471. PubMed ID: 28886127
[TBL] [Abstract][Full Text] [Related]
2. Transcriptomic response of breast cancer cells to anacardic acid.
Schultz DJ; Krishna A; Vittitow SL; Alizadeh-Rad N; Muluhngwi P; Rouchka EC; Klinge CM
Sci Rep; 2018 May; 8(1):8063. PubMed ID: 29795261
[TBL] [Abstract][Full Text] [Related]
3. Anacardic acid inhibits estrogen receptor alpha-DNA binding and reduces target gene transcription and breast cancer cell proliferation.
Schultz DJ; Wickramasinghe NS; Ivanova MM; Isaacs SM; Dougherty SM; Imbert-Fernandez Y; Cunningham AR; Chen C; Klinge CM
Mol Cancer Ther; 2010 Mar; 9(3):594-605. PubMed ID: 20197399
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the miRNA-mRNA-lncRNA networks in ER+ and ER- breast cancer cell lines.
Wu Q; Guo L; Jiang F; Li L; Li Z; Chen F
J Cell Mol Med; 2015 Dec; 19(12):2874-87. PubMed ID: 26416600
[TBL] [Abstract][Full Text] [Related]
5. Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer.
Evangelista AF; Oliveira RJ; O Silva VA; D C Vieira RA; Reis RM; C Marques MM
BMC Cancer; 2021 Jan; 21(1):76. PubMed ID: 33461524
[TBL] [Abstract][Full Text] [Related]
6. All-trans-retinoic acid modulates glycolysis via H19 and telomerase: the role of mir-let-7a in estrogen receptor-positive breast cancer cells.
El Habre R; Aoun R; Tahtouh R; Hilal G
BMC Cancer; 2024 May; 24(1):615. PubMed ID: 38773429
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer.
Ouyang M; Li Y; Ye S; Ma J; Lu L; Lv W; Chang G; Li X; Li Q; Wang S; Wang W
PLoS One; 2014; 9(5):e96228. PubMed ID: 24788655
[TBL] [Abstract][Full Text] [Related]
8. In silico analysis of the association of hsa-miR-16 expression and cell survival in MDA-MB-231 breast cancer cells subjected to photodynamic therapy.
Cupido-Sánchez MG; Herrera-González NE; Mendoza CCB; Hernández MLM; Ramón-Gallegos E
Photodiagnosis Photodyn Ther; 2021 Mar; 33():102106. PubMed ID: 33217568
[TBL] [Abstract][Full Text] [Related]
9. Analysis of serum genome-wide microRNAs for breast cancer detection.
Wu Q; Wang C; Lu Z; Guo L; Ge Q
Clin Chim Acta; 2012 Jul; 413(13-14):1058-65. PubMed ID: 22387599
[TBL] [Abstract][Full Text] [Related]
10. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.
Zhong S; Li W; Chen Z; Xu J; Zhao J
Gene; 2013 Nov; 531(1):8-14. PubMed ID: 23994196
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor beta as epigenetic mediator of miR-10b and miR-145 in mammary cancer.
Piperigkou Z; Franchi M; Götte M; Karamanos NK
Matrix Biol; 2017 Dec; 64():94-111. PubMed ID: 28797712
[TBL] [Abstract][Full Text] [Related]
12. Differential altered expression of let-7a and miR-205 tumor-suppressor miRNAs in different subtypes of breast cancer under treatment with Taxol.
Asghari F; Haghnavaz N; Shanehbandi D; Khaze V; Baradaran B; Kazemi T
Adv Clin Exp Med; 2018 Jul; 27(7):941-945. PubMed ID: 30019863
[TBL] [Abstract][Full Text] [Related]
13. Induction of cell proliferation and survival genes by estradiol-repressed microRNAs in breast cancer cells.
Yu X; Zhang X; Dhakal IB; Beggs M; Kadlubar S; Luo D
BMC Cancer; 2012 Jan; 12():29. PubMed ID: 22260523
[TBL] [Abstract][Full Text] [Related]
14. A panel of miRNAs as prognostic markers for African-American patients with triple negative breast cancer.
Turkistani S; Sugita BM; Fadda P; Marchi R; Afsari A; Naab T; Apprey V; Copeland RL; Campbell MC; Cavalli LR; Kanaan Y
BMC Cancer; 2021 Jul; 21(1):861. PubMed ID: 34315420
[TBL] [Abstract][Full Text] [Related]
15. HNRNPA2/B1 is upregulated in endocrine-resistant LCC9 breast cancer cells and alters the miRNA transcriptome when overexpressed in MCF-7 cells.
Klinge CM; Piell KM; Tooley CS; Rouchka EC
Sci Rep; 2019 Jul; 9(1):9430. PubMed ID: 31263129
[TBL] [Abstract][Full Text] [Related]
16. Differences of time-dependent microRNA expressions in breast cancer cells.
Bozkurt SB; Ozturk B; Kocak N; Unlu A
Noncoding RNA Res; 2021 Mar; 6(1):15-22. PubMed ID: 33385103
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner.
Wang B; Zhang Y; Ye M; Wu J; Ma L; Chen H
Curr Drug Metab; 2019; 20(10):804-814. PubMed ID: 31424364
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.
Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L
Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450
[TBL] [Abstract][Full Text] [Related]
19. Let-7a/cMyc/CCAT1/miR-17-5p Circuit Re-sensitizes Atezolizumab Resistance in Triple Negative Breast Cancer through Modulating PD-L1.
Selem NA; Nafae H; Manie T; Youness RA; Gad MZ
Pathol Res Pract; 2023 Aug; 248():154579. PubMed ID: 37301086
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]